| 1113 |
Adverse Drug Events: H Mono/Poly DR-TB Regimen |
Live |
20/06/2022 |
| 1112 |
Use of Isoniazid [H] Mono/Poly DR-TB Regimen in Special Situations |
Live |
20/06/2022 |
| 1110 |
Replacement Sequence in the H Mono/Poly DR-TB and Shorter Oral Bdq-containing MDR/RR-TB Regimens |
Live |
20/06/2022 |
| 1109 |
Regimen, Duration and Dosage for Isoniazid [H] Mono/Poly DR-TB Regimen |
Live |
20/06/2022 |
| 1108 |
Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation |
Live |
20/06/2022 |
| 1107 |
Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen |
Live |
20/06/2022 |
| 1106 |
Use of Longer Oral M/XDR-TB Regimen in Severe Forms of Extrapulmonary TB and TB Meningitis |
Live |
20/06/2022 |
| 1105 |
Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen |
Live |
20/06/2022 |
| 1104 |
Use of M/XDR-TB Regimen in People Living with HIV [PLHIV] |
Live |
20/06/2022 |
| 1103 |
Clinical Monitoring of DR-TB Patients |
Live |
20/06/2022 |
| 1101 |
Rapid Molecular Drug-resistance Testing |
Live |
20/06/2022 |
| 1091 |
Severity Criteria for Reporting ADRs |
Live |
20/06/2022 |
| 1090 |
Causality Assessment: WHO-UMC [UPSALA Monitoring Centre] Causality Categories for ADR Reporting |
Live |
20/06/2022 |
| 1089 |
Causality Assessment for ADR Reporting |
Live |
20/06/2022 |
| 1088 |
Methods for Pharmacovigilance Activity Reporting [aDSM] |
Live |
20/06/2022 |
| 1070 |
State Airborne Infection Control [AIC] Committee |
Live |
20/06/2022 |
| 1068 |
Requirements for Establishing District DR-TB Centres |
Live |
20/06/2022 |
| 1067 |
Functions of District DR-TB Centre |
Live |
20/06/2022 |
| 1066 |
Mandatory Establishment of DR-TB Centres in All Medical Colleges |
Live |
20/06/2022 |
| 1047 |
Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen |
Live |
20/06/2022 |
| 1046 |
State Airborne Infection Control [AIC] Committee: Terms of Reference [ToR] |
Live |
20/06/2022 |
| 1045 |
State PMDT Committee: Terms of Reference [ToR] |
Live |
20/06/2022 |
| 1044 |
Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen |
Live |
20/06/2022 |
| 1042 |
Common or Relevant Adverse Effects of DR-TB Therapy |
Live |
20/06/2022 |
| 1043 |
Management of QT Prolongation by Grade of Severity of ADR |
Live |
20/06/2022 |
| 1041 |
Immune Reconstitution Inflammatory Syndrome [IRIS] |
Live |
20/06/2022 |
| 1040 |
DR-TB Treatment in Pregnancy: General Considerations |
Live |
20/06/2022 |
| 1039 |
Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up |
Live |
20/06/2022 |
| 1037 |
Pre-treatment Evaluation [PTE] of DR-TB Patients |
Live |
20/06/2022 |
| 1034 |
Key Messages for TB Counselling |
Live |
20/06/2022 |
